search button

Circulating SFRP1 promoter methylation status in gastric adenocarcinoma and esophageal squamous cell carcinoma

  • Authors:
    • Chang Liu
    • Nan Li
    • Heng Lu
    • Zhengkai Wang
    • Chunyan Chen
    • Lin Wu
    • Jiong Liu
    • Youke Lu
    • Fangyu Wang

  • View Affiliations

  • Published online on: November 17, 2014     https://doi.org/10.3892/br.2014.388
  • Pages: 123-127
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The secreted frizzled‑related protein 1 (SFRP1) gene plays an important role in carcinogenesis of digestive system cancer. Previous studies proved that circulating DNA promoter methylation may be a suitable biomarker for cancer patients. The aim of the present study was to investigate whether the promoter methylation status of serum SFRP1 is a potential biomarker for gastric adenocarcinoma (GAC) and esophageal square cell carcinoma (ESCC). The blood samples obtained from 42 GAC and 36 ESCC patients were detected for the promoter methylation status of SFRP1 by methylation‑specific polymerase chain reaction. The control group included 42 benign gastrointestinal disease volunteers (24 benign gastric disease and 18 benign esophageal disease) and 20 healthy volunteers. Serum SFRP1 methylation was evident in 30.95% (13/42) GAC patients and 38.89% (14/36) ESCC patients, which is clearly higher compared to 8.33% (2/24) in benign gastric disease, 11.11% (2/18) in benign esophageal disease and 5% (1/20) in healthy volunteers (P<0.05). The association between the serum SFRP1 promoter methylation status and the clinical pathological features were further analyzed and methylation of the SFRP1 gene was significantly associated with age >60 years in GAC patients (P=0.027). However, no correlations between the SFRP1 methylation status and other clinicopathological parameters were found. In conclusion, the SFRP1 promoter was detected frequently in the serum of GAC and ESCC patients. The detection of circulating methylated SFRP1 in the serum may be a useful biomarker for upper gastrointestinal cancer patients.
View Figures
View References

Related Articles

Journal Cover

January-February 2015
Volume 3 Issue 1

Print ISSN: 2049-9434
Online ISSN:2049-9442

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.3
  • Ranked
    (total number of cites)
  • CiteScore: 4.1
  • CiteScore Rank: Q1: #19/80 Pharmacology, Toxicology and Pharmaceutics
  • Source Normalized Impact per Paper (SNIP): 0.7
  • SCImago Journal Rank (SJR): 0.514
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Liu C, Li N, Lu H, Wang Z, Chen C, Wu L, Liu J, Lu Y and Wang F: Circulating SFRP1 promoter methylation status in gastric adenocarcinoma and esophageal squamous cell carcinoma. Biomed Rep 3: 123-127, 2015.
APA
Liu, C., Li, N., Lu, H., Wang, Z., Chen, C., Wu, L. ... Wang, F. (2015). Circulating SFRP1 promoter methylation status in gastric adenocarcinoma and esophageal squamous cell carcinoma. Biomedical Reports, 3, 123-127. https://doi.org/10.3892/br.2014.388
MLA
Liu, C., Li, N., Lu, H., Wang, Z., Chen, C., Wu, L., Liu, J., Lu, Y., Wang, F."Circulating SFRP1 promoter methylation status in gastric adenocarcinoma and esophageal squamous cell carcinoma". Biomedical Reports 3.1 (2015): 123-127.
Chicago
Liu, C., Li, N., Lu, H., Wang, Z., Chen, C., Wu, L., Liu, J., Lu, Y., Wang, F."Circulating SFRP1 promoter methylation status in gastric adenocarcinoma and esophageal squamous cell carcinoma". Biomedical Reports 3, no. 1 (2015): 123-127. https://doi.org/10.3892/br.2014.388